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clinical effectiveness were obtained from published sources. A
12-month time horizon was adopted, with probabilistic sensi-
tivity analysis and threshold analyses conduced to assess the
impact of uncertainty in parameter estimates. RESULTS: Exam-
ples of published cost-effectiveness analyses included troglita-
zone (PPAR activator, withdrawn in 2000 for hepatotoxicity),
and rofecoxib (COX-2 inhibitor, withdrawn in 2004 for cardio-
vascular toxicity). Despite including ADRs in the analyses, both
drugs were deemed cost-effective. The analysis of treatments for
allergic rhinitis revealed that, in fact, chlorpheniramine had a less
favourable risk/beneﬁt ratio than terfenadine, with a mean dif-
ference of 3.5 QALYs per 1000 patients (95% credible interval,
0.3, 7.6). Threshold analysis suggested that it would require the
relative risk of serious injury with terfenadine, compared with
chlorpheniramine, to increase from 45% to 85%, or for the efﬁ-
cacy of terfenadine to reduce from 60% to 34% for the decision
to be reversed. CONCLUSION: The inclusion in economic eval-
uations of ADRs that are deemed too hazardous to warrant
market authorisation by regulators, may lead to counter-intuitive
estimates of cost-effectiveness. This may be the fault of regula-
tors for not adopting decision analytic models, or reﬂect a lack
of risk aversion in economic evaluations. Alternative explana-
tions are explored.
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OBJECTIVES: To compare the cost-effectiveness of budes-
onide/formoterol in a single inhaler used as Maintenance and
Reliever Therapy (SMART) versus ﬁxed-dose ﬂuticasone/salme-
terol (FD) plus as-needed terbutaline reliever or ﬁxed higher-dose
budesonide/formoterol (FHD) plus as-needed terbutaline reliever
in controlling asthma in adults and adolescents. METHODS:
An economic evaluation was conducted based on the results 
of a large (N = 3335) RCT in which health resource utiliza-
tion was prospectively collected. Primary outcome measure-
ments included time to ﬁrst exacerbation and the number of
severe exacerbations. Costs included direct medical costs (physi-
cian/emergency room visits, hospitalizations, asthma drug costs)
and productivity (absenteeism). The time horizon was six-
months which corresponded to the duration of the trial. Prices
were obtained from 2006 Canadian sources. Both health care
(HC) and societal (Soc) perspectives were considered. Determin-
istic univariate sensitivity analyses were conducted. RESULTS:
In the clinical trial, SMART was superior to FD (p < 0.001) and
FHD (p = 0.0048). Exacerbation rates (reported as per patient
per 6 months) were 0.12 for SMART, 0.19 for FD, and 0.16 for
FHD. All treatments provided similar improvements in lung
function, asthma control days and asthma-related quality of life.
From the HC perspective, the mean cost per patient per 6 months
was $583 in the SMART arm versus $867 in the FD arm versus
$737 in the FHD arm. From the Soc perspective, it was $633 for
SMART, $914 for FD and $799 for FHD. SMART was domi-
nant (more effective, less expensive) in the base case analysis
from both the HC and Soc perspectives. The results were robust
under sensitivity testing. CONCLUSION: The SMART strategy
which allows budesonide/formoterol to be used as both mainte-
nance and reliever medication is dominant over a strategy of
ﬁxed dose salmeterol and ﬂuticasone plus as-needed terbutaline
and ﬁxed higher dose budesonide and formoterol plus as-needed
terbutaline.
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OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a
marker for the airway inﬂammation underlying asthma. NIOX
is a non-invasive, user-friendly FENO monitor that can be used
in physicians’ ofﬁces to provide immediate information on
patient response to anti-inﬂammatory treatment. The objective
of this study was to assess the cost-effectiveness of NIOX in
asthma diagnosis and management in the US. METHODS: Based
on a literature review, two decision trees were constructed to
capture the different alternatives and consequences in asthma
diagnosis and management, comparing FENO measurement
against standard diagnostics and treatment guidelines. The
impact of asthma management with FENO measurement on
resource use and health outcomes was evaluated over a 1-year
timeframe. A US payer perspective was chosen, using 2006 costs
from standard sources. Effectiveness was measured in quality-
adjusted life-years (QALYs). RESULTS: Asthma diagnosis based
on NIOX results in a cost of $29 per patient, including the cost
of false diagnoses, compared to $49 for standard diagnostics
(spirometry, reversibility testing, bronchoprovocation, sputum
eosinophil count). In mild to severe patients, asthma manage-
ment with FENO measurement instead of spirometry leads to
0.06 QALYs gained and cost-savings of $350 per patient and
year, of which $295 stem from reduced hospitalisations and $5
from lower doses of inhaled corticosteroids (ICS). In a more
severe population, management with NIOX would save $1350
($1250 from hospitalisations and $55 from reduced ICS doses)
and 0.004 QALYs per patient. Based on four visits per year, the
cost of monitoring would be reduced by $50 per patient with
NIOX. CONCLUSION: Asthma diagnosis based on NIOX
alone is less costly and more accurate than standard diagnostic
methods. The use of FENO measurement in treatment decisions
is less costly than asthma management based on standard guide-
lines and provides similar health beneﬁts.
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OBJECTIVES: Studies in patients with asthma and COPD have
demonstrated that levalbuterol (LEV) treatment resulted in sig-
niﬁcantly fewer nebulizations and/or decreased total cost of care
compared with racemic albuterol (RAC). This was a prospective,
multicenter, open-label study in patients hospitalized for acute
bronchospasm that evaluated the cost-effectiveness of the two
treatments. METHODS: Patients were randomized to either
LEV 1.25 mg (N = 241) Q8h or RAC 2.5 mg (N = 238), admin-
istered per routine standing hospital order. The primary endpoint
was the total number of nebulizations (scheduled plus rescue)
during hospitalization. Secondary endpoints included length and
cost of hospital stay. Cost-effectiveness (CE) analyses were con-
